Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Sokolova on Talazoparib Plus Enzalutamide in mCRPC

June 1st 2023

Alexandra Sokolova, MD, discusses key findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer and unanswered questions regarding the use of PARP inhibitors plus androgen receptor inhibitors in patients with biomarker-negative disease.

EMA Committee Recommends Piflufolastat 18F PSMA PET Imaging Agent for Prostate Cancer

June 1st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of piflufolastat 18F, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent, for use in prostate cancer detection.

Dr Wise on the Deciding Between Doublet and Triplet Regimens in Prostate Cancer

May 31st 2023

David R. Wise, MD, PhD, discusses considerations for the use of doublet or triplet regimens for the treatment of patients with prostate cancer.

Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC

May 31st 2023

Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Dr Stone on the Investigation of Limited English Proficiency and PSA Screening Rates in Prostate Cancer

May 31st 2023

Benjamin V. Stone, MD, discusses clinical implications derived from a retrospective study on the effect of limited English proficiency on prostate-specific antigen screening rates in American men with prostate cancer, as well as the need to improve equitable access to PSA screening across academic and community centers.

Dr. Tagawa on the Evolution and Selection of PARP Inhibitors in mCRPC

May 30th 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of PARP inhibitor use in metastatic castration-resistant prostate cancer and available PARP inhibitors for molecularly-selected patients in this space.

FDA Approves First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30th 2023

The FDA has approved flotufolastat F 18 injection (Posluma) for positron emission tomography of prostate-specific membrane antigen–positive lesions in men with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen level.

Dr Wise on the Optimal Use of Treatment Intensification in mHSPC

May 25th 2023

David R. Wise, MD, PhD, discusses changes in the optimal use of intensified treatment regimens in patients with metastatic hormone-sensitive prostate cancer.

IO Therapy in mCRPC and Clinical Pearls

May 24th 2023

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

Practical Application of PARP Inhibitors in Metastatic CRPC

May 24th 2023

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Dr Stone on the Association of Language Barriers and PSA Screening for Prostate Cancer

May 19th 2023

Benjamin V. Stone, MD, discusses the association between language barriers and prostate-specific antigen screening rates in American men.

Link Between PSA Response and Survival Outcomes Supports Use of Darolutamide Plus ADT/Docetaxel as a SOC in mHSPC

May 18th 2023

Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.

Dr Cole on the Rationale for Investigating Race-based Disparities in Prostate Cancer–Specific Survival

May 18th 2023

Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.

Real-world Evidence Provides More Accurate Representation of Next-generation AR Inhibitor Use and Efficacy in mCSPC

May 17th 2023

Benjamin H. Lowentritt, MD, FACS, highlights key findings from the retrospective study of second-generation ARSI use in patients with metastatic castration-sensitive prostate cancer treated in clinic and discusses several directions for future analyses of real-world outcomes in prostate cancer.

Metastatic CRPC: Advent of PARP Inhibitors

May 17th 2023

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm

May 17th 2023

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

Study Sheds Light on Effect of Type of Treatment on Race-based Differences in Prostate Cancer–Specific Survival

May 15th 2023

Alexander Putnam Cole, MD, discusses the importance of investigating racial and ethnic disparities in prostate cancer outcomes, key data from a comparison of cancer-specific survival according to race and treatment modality, and how these results could better inform efforts to improve access to, and quality of, patient care in this disease.

Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

May 11th 2023

Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.

Updated Findings Spur Excitement In nmCRPC, mHSPC, mCRPC

May 11th 2023

An increased focus on long-term and genomic analyses on established treatments in prostate cancer have revealed new opportunities for patients across disease states.

Dr Shore on the Rationale for the EMBARK Trial in Nonmetastatic Prostate Cancer

May 10th 2023

Neal Shore, MD, FACS, discusses the rationale for the phase 3 EMBARK trial investigating enzalutamide plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.